dc.contributor.author | Jalili, Mahsa | |
dc.contributor.author | Hekmatdoost, Azita | |
dc.contributor.author | Vahedi, Homayoon | |
dc.contributor.author | Poustchi, Hossein | |
dc.contributor.author | Khademi, Behnam | |
dc.contributor.author | Saadi, Mohsen | |
dc.contributor.author | Zemestani, Maryam | |
dc.contributor.author | Janani, Leila | |
dc.date.accessioned | 2020-04-29T12:37:10Z | |
dc.date.available | 2020-04-29T12:37:10Z | |
dc.date.created | 2016-11-02T14:15:16Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | PLOS ONE. 2016, 11 (8), . | en_US |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/11250/2652945 | |
dc.description.abstract | Background and Aims
The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estrogens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles. The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS.
Methods
In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were randomly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D was one pearl of 50’000 IU biweekly. The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other.
Results
IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and D+P groups (p-value = 0.001, 0.047 respectively).
Conclusion
Our results indicate that co-administration of soy isoflavones with vitamin D did not improve the IBS- SSS and IBS- QOL; however, it improved the IBS-TS. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | PLOS, Public Library of Science | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Co-Administration of soy isoflavones and Vitamin D in management of irritable bowel disease | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 11 | en_US |
dc.source.volume | 11 | en_US |
dc.source.journal | PLOS ONE | en_US |
dc.source.issue | 8 | en_US |
dc.identifier.doi | 10.1371/journal.pone.0158545 | |
dc.identifier.cristin | 1396647 | |
dc.description.localcode | Copyright: © 2016 Jalili et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |